Actinium Pharmaceuticals develops targeted radiotherapies for cancer using its Antibody Radiation Conjugates platform and alpha-emitting radioisotopes. Company updates commonly focus on ATNM-400, an Actinium-225 antibody radioconjugate studied in solid tumor models including prostate, lung, and breast cancer, and Actimab-A, or lintuzumab-Ac225, an Actinium-225 therapy targeting CD33 in acute myeloid leukemia.
Additional announcements describe radiochemistry work such as chelator-to-antibody ratio optimization, preclinical data presented at oncology and nuclear medicine meetings, and the company's broader radiotherapy platform across solid tumors, hematologic malignancies, and conditioning for cellular therapies.
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) announced its management will participate in a fireside chat at the 3rd Annual B. Riley Securities Oncology Conference on January 19, 2023, at 10:30 AM EST. The event will showcase over 30 small and mid-cap healthcare companies focusing on innovative cancer therapies. Actinium is known for its advanced radiotherapy products, including I-131 apamistamab (Iomab-B), which has shown positive results in clinical trials for treating acute myeloid leukemia. The presentation will be available for replay on Actinium's website and the conference site.
Actinium Pharmaceuticals (ATNM) announced that the full data from its pivotal Phase 3 SIERRA trial of Iomab-B will be presented at the TCT Tandem Meetings on February 18, 2023. The SIERRA trial met its primary endpoint with a statistically significant p-value of <0.0001, indicating durable Complete Remission in older patients with acute myeloid leukemia. Following the presentation, the company plans a conference call at 6:00 PM EST on the same day. Iomab-B aims to improve access to bone marrow transplants, having shown increased survival rates in prior studies.
Actinium Pharmaceuticals (NYSE: ATNM) reported positive survival data from its Actimab-A and CLAG-M combination trial for relapsed or refractory acute myeloid leukemia (AML) patients. Key findings include a 59% one-year overall survival for patients previously treated with Venetoclax, 75% measurable residual disease negativity, and a manageable safety profile. Notably, patients with a TP53 mutation showed a 52% one-year overall survival. These results were shared at the 64th Annual ASH Meeting, emphasizing the potential of Actimab-A as a treatment for high-risk AML patients previously deemed difficult to treat.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has announced a collaboration with Columbia University to study Actimab-A, a targeted radiotherapy for acute myeloid leukemia (AML). The partnership focuses on the use of gene-edited hematopoietic stem cells (eHSCs) to eliminate residual leukemia cells post-transplant. Preliminary results show promising data: 53% one-year and 32% two-year overall survival rates, with a 67% overall response rate and 72% measurable residual disease negativity in patients. The findings will be presented at the American Society of Hematology Annual Meeting on December 10, 2022.
Actinium Pharmaceuticals (ATNM) showcased promising results from its Phase 1 trial of Actimab-A combined with CLAG-M in treating relapsed or refractory acute myeloid leukemia (AML). Highlights include a median overall survival of 12 months, with 1-year and 2-year survival rates at 53% and 32%, respectively—significantly higher than existing treatments. The trial involved patients with adverse cytogenetics, including TP53 mutations. Data will be presented at the ASH Annual Meeting on December 10, 2022, enhancing the potential for Actimab-A's use as a backbone therapy in AML.
Actinium Pharmaceuticals has appointed Caroline Yarbrough as Chief Commercial Officer to lead the commercialization of Iomab-B. Previously with Novartis, Caroline has extensive experience in oncology and managing billion-dollar portfolios. CEO Sandesh Seth emphasized her expertise in launching cancer therapies and her role in expanding access to bone marrow transplants for elderly patients with acute myeloid leukemia. The company aims to file a Biologics License Application for Iomab-B, which recently showed significant efficacy in a pivotal Phase 3 trial.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced positive results from its pivotal Phase 3 SIERRA trial of Iomab-B for treating elderly patients with active relapsed or refractory acute myeloid leukemia (AML). The trial met its primary endpoint, achieving a durable complete remission (dCR) of 6 months post-treatment, with a p-value of <0.0001. Iomab-B demonstrated significant potential to increase patient access to bone marrow transplants (BMT) and improve patient outcomes, prompting the company to advance its Biologics License Application (BLA) submission to the FDA.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) announced a senior-level expansion of its clinical organization, strengthening its expertise in bone marrow transplant and acute myeloid leukemia. Key hires include Madhuri Vusirikala, MD, Akash Nahar, MD, Patrik Brodin, Ph.D., and Elaina Haeuber, enhancing the company's operational capabilities for pivotal programs Iomab-B and Actimab-A. Topline data from the Phase 3 SIERRA trial for Iomab-B is expected in Q4 2022. This expansion aims to advance clinical development and improve patient outcomes in hematological malignancies.
Actinium Pharmaceuticals, Inc. (NYSE: ATNM) will participate in the virtual Bio-Europe conference from November 2-4, 2022. The event is the largest biopharma partnering meeting in Europe, featuring over 4,000 attendees and 27,000 scheduled 1-on-1 meetings. Actinium's business development team will conduct individual meetings, which can be requested through the partneringONE® system. The company focuses on targeted radiotherapies for cancer treatment, with key products including I-131 apamistamab (Iomab-B) and Actimab-A, both undergoing clinical trials.
Actinium Pharmaceuticals (NYSE AMERICAN: ATNM) has appointed several key executives to strengthen its leadership team. Jenny Hsieh joins as Chief Strategy Officer, having previously led corporate strategy at Immunomedics. Sunitha Lakshminarayanan takes on the role of Senior Vice President, Head of CMC and Product Development, bringing extensive experience from Bristol Myers Squibb. Stephen Dressel is appointed Vice President of Strategic Finance and Analysis, with a background in finance at Regeneron. These additions come as the company prepares for pivotal clinical data results from the Iomab-B SIERRA trial and Actimab-A CLAG-M combination trial.